论文部分内容阅读
目的:评价FOLFOX4化疗方案联合塞来昔布和奥曲肽治疗进展期胃癌的疗效、安全性、生存期及生活质量。方法:将胃癌患者50例随机分为观察组和对照组各25例。对照组行常规化疗;观察组在常规化疗基础上给予口服塞来昔布200 mg,皮下注射奥曲肽100μg,均为每天1次,21天为1个周期。结果:两组有效率、临床获益率、不良反应比较,差异不显著(P>0.05);中位疾病进展时间(7.9个月)、中位生存期(13.2个月)及生存质量改善率(76%)比较,差异显著(P<0.05)。结论:FOLFOX4方案联合塞来昔布和奥曲肽治疗进展期胃癌疗效较单用化疗方案好,能提高生存期,改善患者生活质量。
Objective: To evaluate the efficacy, safety, survival and quality of life of FOLFOX4 chemotherapy combined with celecoxib and octreotide in the treatment of advanced gastric cancer. Methods: 50 patients with gastric cancer were randomly divided into observation group and control group, 25 cases each. The control group received routine chemotherapy. The observation group was given oral celecoxib 200 mg on the basis of routine chemotherapy and subcutaneous injection of octreotide 100 μg once a day for 21 days. Results: There was no significant difference in the effective rate, clinical benefit rate and adverse reaction between the two groups (P> 0.05). The median disease progression time (7.9 months), median survival time (13.2 months) and quality of life improvement (76%), the difference was significant (P <0.05). Conclusion: FOLFOX4 combined with celecoxib and octreotide is more effective than chemotherapy alone in the treatment of advanced gastric cancer, which can improve the survival and improve the quality of life of patients.